Status:
UNKNOWN
Non-Invasive Determination of Fetal Chromosome Abnormalities
Lead Sponsor:
Lenetix Medical Screening Laboratory
Conditions:
Down Syndrome (Trisomy 21)
Edward's Syndrome (Trisomy 18)
Eligibility:
FEMALE
18+ years
Brief Summary
The overall significance of this study is to develop a laboratory developed test (LDT) to use a new marker in the maternal blood to better identify pregnancies that have a child with a chromosome abno...
Eligibility Criteria
Inclusion
- This study is only applicable to women who are between 8 and 30 weeks' gestation and who have been determined increased risk for fetal aneuploidy. In the interest of expediting and simplifying this study, the investigators want only women who have already decided to undergo second-trimester amniocentesis or CVS.
Exclusion
- The only exclusion criteria are those mentioned.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00891852
Start Date
January 1 2009
End Date
December 1 2009
Last Update
May 1 2009
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Maryland Perinatal Associates
Rockville, Maryland, United States, 20850
2
Atlantic Maternal Fetal Medicine
Moristown, New Jersey, United States, 07960
3
Winthrop University Hospital
Mineola, New York, United States, 11501
4
Elite Women's Health
New Hyde Park, New York, United States, 11042